Immatics N.V.
NASDAQ:IMTXBiotechnology
+$0.15 today
- Market cap
- $912.78M
- Beta
- 1.30
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.59
Volume 1.57M
Average 0.46M
IMTX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Immatics N.V.NASDAQ: IMTX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns positive
Q1 FY2026 other income / expenses was €8.3M, compared with -€5.48M a year earlier. Trailing-twelve-month other income / expenses was -€2.64M.
Context
- Other income / expenses amounted to 34.0% of revenue in FY2025, down 4.5 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near €8.3M or moves back toward the trailing-twelve-month quarterly average of -€660.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
EUR · from the income statement
- Latest · FY2025
- (16.42M) EUR
- Year-over-year change
- -127.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (16.42M) | -127.4% |
| FY2024 | 2024-12-31 | 59.96M | +1167.4% |
| FY2023 | 2023-12-31 | 4.73M | -60.8% |
| FY2022 | 2022-12-31 | 12.08M | +271.6% |
| FY2021 | 2021-12-31 | (7.04M) | — |
Other Income / Expenses vs competitors
How IMTX compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -106.2% is the 8th highest of 11, against a peer median of -41.6%.
- Other income / expenses amounts to 7.1% of revenue for IMTX, versus a peer median of 13.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €260.88M EUR | -46.5% | — | 9.9% | |
| LTM Mar 2026 | $42.51M USD | +18.6% | +121.9% | 196.7% | |
| LTM Mar 2026 | $21.54M USD | -13.2% | +29.7% | 5.6% | |
| LTM Mar 2026 | $16.46M USD | -3.2% | — | — | |
| LTM Mar 2026 | $4.4M USD | -46.5% | +144.2% | 48.1% | |
| LTM Sep 2026 | -$1.9M USD | +94.1% | — | 0.1% | |
| LTM Mar 2026 | -€2.64M EUR | -106.2% | — | 7.1% | |
| LTM Mar 2026 | -$3.13M USD | -36.7% | — | 13.5% | |
| LTM Mar 2026 | -$5.37M USD | -124.3% | — | 11.9% | |
| LTM Mar 2026 | -$23.45M USD | -215.6% | — | 34.4% | |
| LTM Mar 2026 | -$54.54M USD | -309.6% | — | 175948.4% | |
| Peer median (excluding IMTX) | — | -41.6% | +121.9% | 13.5% | |
Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.76M | 172.83M | 54M | 155.84M | 48.27M |
| Cost of Revenue | 87.57M | 106.78M | 118.66M | 0 | 0 |
| Gross Profit | (52.81M) | 66.05M | (64.67M) | 155.84M | 48.27M |
| Gross Margin | -151.9% | 38.2% | -119.8% | 100.0% | 100.0% |
| Research & Development | 87.57M | 106.78M | 118.66M | 148.08M | 183.83M |
| Selling, General & Admin | 33.81M | 36.12M | 38.2M | 46.45M | 51.18M |
| Operating Expenses | 121.05M | 142.88M | 155.72M | 194.45M | 230.28M |
| Depreciation & Amortization | 5.47M | 6.84M | 7.23M | 12.23M | 12.4M |
| EBITDA | (87.3M) | 50.04M | (88.93M) | 34.46M | (185.09M) |
| EBITDA Margin | -251.1% | 29.0% | -164.7% | 22.1% | -383.5% |
| Operating Income | (86.29M) | 29.95M | (101.73M) | (38.62M) | (182.02M) |
| Operating Margin | -248.2% | 17.3% | -188.4% | -24.8% | -377.1% |
| Interest Income | 133K | 2.48M | 13.85M | 25M | 17.18M |
| Interest Expense | 566K | 1.04M | 831K | 886K | 946K |
| Other Income / Expenses | (7.04M) | 12.08M | 4.73M | 59.96M | (16.42M) |
| Income Before Tax | (93.34M) | 42.04M | (96.99M) | 21.35M | (198.44M) |
| Pre-Tax Margin | -268.5% | 24.3% | -179.6% | 13.7% | -411.1% |
| Income Tax Expense | 0 | 4.55M | 0 | 6.13M | (1.99M) |
| Net Income | (95.06M) | 37.51M | (96.99M) | 15.22M | (196.45M) |
| Net Margin | -273.5% | 21.7% | -179.6% | 9.8% | -407.0% |
| EPS (Basic) | (1.51) | 0.55 | (1.20) | 0.14 | (1.54) |
| EPS (Diluted) | (1.51) | 0.54 | (1.20) | 0.14 | (1.54) |
| Weighted Avg Shares | 62.91M | 67.22M | 80.55M | 108.7M | 122.35M |
| Weighted Avg Shares (Diluted) | 62.91M | 68.82M | 80.55M | 106.8M | 122.35M |
Immatics N.V.
NASDAQ:IMTX
Intrinsic Alpha fair value
Locked
Current Price
$6.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.